NEW YORK, Dec. 8, 2011 /PRNewswire/ -- Kipley J.
Lytel, CFA and Senior Analyst with New
York based independent research firm Prime Equity Research,
LLC, has initiated research coverage on AtheroNova Inc. (OTCBB:
AHRO).
For free access to the report and information on Prime Equity
Research, LLC, please visit the Company's website. Interested
parties may obtain the report at www.primeequityresearch.com.
Prime Equity Research advises investors to exercise a reasonable
degree of due diligence before trading in the equities of any
public company, including carefully reading entire analyst reports
and report disclosures, and then only in conjunction with advice
from a registered financial advisor or broker. Prime Equity
Research further advises that any analyst rating, recommendation,
target valuation, price target or opinion should be considered
merely a portion of an investor's total investigative process.
About AtheroNova Inc.
AtheroNova Inc. is a development stage company focused on the
discovery, research, development and licensing of novel compounds
designed to reduce or eliminate atherosclerotic plaque deposits.
AtheroNova has developed intellectual property for a class of
compounds that has the potential to significantly reduce the
incidence and severity of atherosclerosis. The company was founded
in 2006 and is based in Irvine,
California.
Additional information can be found on the company's website at
www.atheronova.com.
About Prime Equity Research
Prime Equity Research was founded and is managed by a team that
has been actively involved in the research and finance industry for
over 20 years -- dating back to the origins of corporate-sponsored
research. Our business is rooted in principles of integrity and
fundamentals-driven markets. Our seasoned pool of equity securities
analysts have extensive securities market research experience, and
are highly qualified and credentialed CFA (Chartered Financial
Analyst) charter holders or MBAs. The research we provide is as
comprehensive, and unbiased as any on the market. Our reports
and ratings are used by both institutional and individual investors
to obtain accurate, independently-compiled securities data and
takes steps to ensure the independence and integrity of published
research that exceed those of the CFA Institute Code of Ethics and
Standards of Professional Conduct and the CFA-NIRI Guidelines, by
following the exacting "Standards for Independent Research
Providers", which are also in accordance with guidance set forth by
U.S. Securities and Exchange Commission's Advisory Committee on
Smaller Public Companies.
Statements in this press release may be "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as "optimizing," "potential,"
"anticipate," "goal," "intend" and similar expressions, as they
relate to the company or its management, identify forward-looking
statements. These statements are based on current expectations,
estimates and projections about the company's business based, in
part, on assumptions made by management. These statements are not
guarantees of future performance and involve risks, uncertainties
and assumptions that are difficult to predict. Actual outcomes and
results may, and probably will, differ materially from what is
expressed or forecasted in such forward-looking statements due to
numerous factors, including those described above and those risks
discussed from time to time in AtheroNova, Inc. filings with the
Securities and Exchange Commission. The company notes that the
numbers contained in this release are unaudited, and are made in
good faith and based on all the financial information available to
the company today. Further, past financial business, operations and
stock performance are not necessarily indicative of the company's
future performance. The opinions expressed in the research report
are the analyst's personal views about the company. Definitions of
ratings are available to the public and to the analysts. No rating
is to be issued that is labeled a recommendation. No analyst may
recommend the purchase or the sale of any equity. The analyst is
responsible only to the public and this report is not a service to
the company. The report is for information purposes and is not
intended as an offering or a solicitation to buy or sell the
securities mentioned above. Neither the analyst nor Prime Equity
Research owns any equity or debt securities in the analyzed
company. Analysts are independent contractors and not employed by
Prime Equity Research. The analyst is paid in advance to ensure
independent and objective opinions are rendered without conflict.
AtheroNova, Inc. and a Third party paid Prime Equity Research
$12,500 for independent equity
coverage. The following is from the Final Report of the SEC
Advisory Committee on Smaller Public Companies, adopted
February 21, 2006:
www.sec.gov/info/smallbus/acspc/acspc-finalreport.pdf "In
order to address the need for more independent research for smaller
public companies, [the U.S. Securities and Exchange Advisory
Committee on Smaller Public Companies recommends] that the
Commission: "Maintain policies that allow company-sponsored
research to occur with full disclosure by the research provider as
to the nature of the relationship with the company being covered.
"Entities providing such research should disclose and adhere to a
set of ethical standards* that ensure quality and transparency and
minimize conflicts of interest."
SOURCE AtheroNova Inc.